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Cyadox (Cyx) is an antibacterial drug of the quinoxaline group that exerts markedly
lower toxicity in animals, compared to its congeners. Here, the pharmacokinetics and
metabolism of Cyx after oral (PO), intramuscular (IM), and intravenous (IV) routes of
administration were studied to establish safety criteria for the clinical use of Cyx in
animals. Six beagle dogs (3 males, 3 females) were administered Cyx through PO (40mg
kg−1 b.w.), IM (10mg kg−1 b.w.), and IV (10mg kg−1 b.w.) routes with a washout
period of 2 weeks in a crossover design. Highly sensitive high-performance liquid
chromatography with ultraviolet detection (HPLC-UV) was employed for determination of
Cyx and its main metabolites, 1, 4-bisdesoxycyadox (Cy1), cyadox-1-monoxide (Cy2),
N-(quinoxaline-2-methyl)-cyanide acetyl hydrazine (Cy4), and quinoxaline-2-carboxylic
acid (Cy6) in plasma, urine and feces of dogs. The oral bioavailability of Cyx was 4.75%,
suggesting first-pass effect in dogs. The concentration vs. time profile in plasma after
PO administration indicates that Cyx is rapidly dissociated into its metabolites and
eliminated from plasma earlier, compared to its metabolites. The areas under the curve
(AUC) of Cyx after PO, IM and IV administration were 1.22 h × µg mL−1, 6.3 h × µg
mL−1, and 6.66 h × µg mL−1, while mean resident times (MRT) were 7.32, 3.58 and
0.556 h, respectively. Total recovery of Cyx and its metabolites was >60% with each
administration route. In feces, 48.83% drug was recovered after PO administration, while
18.15% and 17.11% after IM and IV injections, respectively, suggesting renal clearance
as the major route of excretion with IM and IV administration and feces as the major
route with PO delivery. Our comprehensive evaluation of Cyx has uncovered detailed
information that should facilitate its judicious use in animals by improving understanding
of its pharmacology.
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INTRODUCTION
Quinoxaline 1, 4-di-N-oxide (QdNO) derivatives are effective
synthetic antibacterial agents used worldwide since 1970 to treat
several gram-positive and gram-negative bacterial infections in
animals (Wang et al., 2015a,b; Cheng et al., 2016). Olaquindox,
mequindox, and carbadox are the well-known members of
this group, but have been banned or strictly limited to use
due to their potential toxicities in animals. Cyadox (Cyx),
2-formylquinoxaline-N1, N4-dioxide cyanocetylhydrazone, is
a novel derivative of QdNO, and a promising antibacterial
agent believed to be safer for use than its congeners (Fan
et al., 2000; Fang et al., 2006; Wang et al., 2015c). It has
been characterized as an effective broad-spectrum antibacterial
agent against the majority of pathogenic bacteria (including
Staphylococcus, Pasturella, and Salmonella spps) in animals (Fan
et al., 2000; Huang et al., 2002; Wang et al., 2005). Cyx has been
recommended as the drug of choice to prevent Escherichia coli
infection in pigs and chickens owing to the lack of toxic effects
(Wang et al., 2005; Ding et al., 2006a,b). Dogs are generally
more prone to these types of bacterial infections (Angus et al.,
1997; Greene, 2013; Lowden et al., 2015). The findings to date
support the efficacy of Cyx as a safe and effective quinoxaline-
based antibacterial agent in different animal species, including
canines.
During the drug development process, failures are often
attributed due to adverse pharmacokinetic properties of the
tested compounds. Bioavailability and desirable half-life are the
key parameters for consideration to establish the success of newly
formed drugs. Accurate assessment of pharmacokinetics and
affecting factors is necessary for effective drug design. Therefore,
pharmacokinetic and metabolic profiles should be taken into
consideration to facilitate rational drug design (Lin and Lu,
1997). Dogs have long been used as a model in drug development
and discovery research due to their anatomical and physiological
resemblance with other mammals (Smith, 1991; Khanna et al.,
2006; Rowell et al., 2011) and thus regarded as optimal choice
for evaluation of new drugs, in view of the similarities between
the pharmacokinetic and metabolism profiles (Smith, 1991; Lin,
1995; Chiou et al., 2000; Weinz et al., 2009). Many studies have
been conducted using dogs as a surrogate for humans (Sande and
Johnson, 1975; Rossi et al., 2004; Knapp et al., 2014; Lin et al.,
2015; Piras et al., 2015). Evaluation of metabolism, distribution
and excretion are of vital importance for determining the fate of
a particular drug within the body. Numerous in vitro and in vivo
studies have demonstrated that Cyx is extensively metabolized
through different pathways and many kinds of metabolites
identified in pigs, chicken, carp, and rats (Liu et al., 2009; Xu
et al., 2011; Huang et al., 2015). Furthermore, some approaches
for the quantification of Cyx and its variousmetabolites in animal
tissues have been described (Huang et al., 2008; Cheng et al.,
2012; Yan et al., 2012). Tissue depletion and pharmacokinetics
of Cyx and its main metabolites following oral administration
in pigs were recently investigated (Li et al., 2013; Zhao et al.,
2013). However, comprehensive pharmacokinetics, distribution
and depletion profiles of Cyx in rodents and non-rodents are
yet to be completely established. To date, a small number of
studies have focused on the pharmacokinetic properties of Cyx
without considering its main metabolites (Qiu, 2003; Yin, 2003;
Huang, 2005). Given that Cyx is metabolized extensively and
rapidly in the body (Liu et al., 2009; Xu et al., 2011), the main
metabolites of Cyx must be well thought-out during metabolism
and pharmacokinetic studies for clarification of the fate of the
drug. Previous studies conducted by the team of National Basic
Research Program of China (973 Program, 2009CB118800) and
other research groups have disclosed that 1, 4-bisdesoxycyadox
(Cy1), cyadox-1-monoxide (Cy2), N-(quinoxaline-2-methyl)-
cyanide acetyl hydrazine (Cy4) and quinoxaline-2-carboxylic
acid (Cy6) are the main metabolites of Cyx in different animals
(Zhao et al., 2013; Huang et al., 2015). Information on the
metabolism and pharmacokinetic properties of Cyx and its main
metabolites is therefore critical for comprehensive assessment of
the fate of the drug in animals to ensure its judicious use as an
antibacterial.
Cyx is less toxic in non-rodents, compared to other QdNO
derivatives (Wang et al., 2015c). To our knowledge, no relevant
studies on Cyx to establish safety criteria have been reported
in non-rodents. In view of the physiological similarities of dogs
with humans and other animals, the present study aimed to
explore the metabolism and pharmacokinetic profiles of Cyx and
its main metabolites (Cy1, Cy2, Cy4, and Cy6) in beagle dogs
following oral (PO), intramuscular (IM), and intravenous (IV)
administration using high-performance liquid chromatography
with ultraviolet (HPLC-UV) detection. Our results should be
useful for the assessment of efficacy, safety and effective dosage
regimens of Cyx for clinical use.
MATERIALS AND METHODS
Chemicals
Cyx (≥98%) and its four metabolites Cy1, Cy2, Cy4, and Cy6
were synthesized at the Veterinary Institute of Pharmaceuticals
in Huazhong Agricultural University (Wuhan, PR China).
HPLC-grade acetonitrile (ACN) and methanol (MeOH) were
purchased from Fisher Chemicals Co. (New Jersey, USA). Oasis
HLB cartridges (3mL, 60 mg) were acquired from Waters
(Milford, MA, USA). Polyvinylpyrrolidone K30 (PVP), sodium
hydroxide (NaOH), hydrochloric acid (HCl), dimethyl sulfoxide
(DMSO), sodium chloride (NaCl), and trichloromethane (TCM)
were obtained from Sinopharm Chemical Reagent Co., LTD
(Shanghai, PR China). Water was purified using the Milli-Q
water purification system (Milli-Q Co., Ltd, France). All other
chemicals and reagents used were of high analytical grade.
Solution Preparation
Standard stock solutions of Cyx, Cy1, Cy2, Cy4, and Cy6
were prepared individually by dissolving in DMSO and stored
at −20◦C in the dark. All metabolites were mixed together
and different concentrations (10–100µg mL−1) prepared using
MeOH before storage at 4◦C for further use.
Formulation Preparation
Cyx suspension (80mg mL−1) was prepared for PO
administration in dogs by dissolving an appropriate amount
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into 0.5% sodium carboxymethyl cellulose aqueous solution.
Due to the likelihood of increased toxicity of Cyx upon
dissolving in DMSO, suitable suspension for IM and IV routes
of administration was generated by recrystallization based
on acid-base neutralization for safe use in animals. Initially,
a number of solutions were prepared in advance, including
NaOH (12mol L−1), 1% PVP and HCl (12mol L−1). The
NaOH solution (15mL) was poured into a 200mL volumetric
flask containing 20mL 1% PVP stabilizer under stirring using
a thermostat magnetic stirrer (90-1, Shanghai HuXi analysis
instrument factory Co., Ltd., Shanghai, PR China) and 1 g of
Cyx subsequently added. After Cyx was completely dissolved,
15mL HCl was dissolved for acid-base neutralization. A uniform
suspension of Cyx (50mL) was obtained at a concentration of
20mg mL−1. The viability of the stock solution was determined
using a UV spectrophotometer before IM and IV injection into
dogs.
Animals
Three male and three female healthy Beagle dogs 5–6 months
of age with uniform weights (9–10 kg) were purchased from the
Experimental Animal Center of Tongji University (Wuhan, PR
China). Animals were maintained under conditions of ambient
temperature (22 ± 2◦C) with 45–65% relative humidity. Air
ventilation was provided every 30min. Dogs were fed 350 g
certified commercial diet (Ke Ao Xie Li Co. Ltd., Beijing, PR
China) at a fixed time per day, with tap water provided ad libitum
throughout the experiment. Each dog was kept in an isolated steel
cage (1000 × 10,000 × 900mm) with a specific ear tag number
2 weeks before the start of the experiment for acclimatization.
Identification numbers were also attached to every cage. All dogs
enjoyed outside walk at least once a week. This experiment was
performed in accordance with NIH publication 85–23 “Guide
for the Care and Use of Laboratory Animals” (NRC, 1996) and
approved by the Ethical Committee of the Faculty of Veterinary
Medicine at Huazhong Agricultural University.
Dose Administration and Sampling
A randomized crossover design with a 2-week washout period
was employed. PO administration was achieved through gavage
at a dose rate of 40mg kg−1 b.w., and the blood (1mL) collected
from the cephalic vein in heparin-containing tubes before and
after 0.25, 0.50, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 24, 36, and
48 h of administration. IM administration was achieved through
injection into the quadricep muscle within the thigh region at
a dose rate of 10mg kg−1 b.w., and blood (1mL) collected in
heparin-containing tubes before and after 0.25, 0.5, 0.75, 1, 2, 3, 4,
5, 6, 7, 8, 10, 12, 16 and 24 h of injection. For IV administration,
the drug was injected into the cephalic vein at a dose rate of 10mg
kg−1 b.w., and blood (1mL) collected in heparin-containing
tubes before and after 0.033, 0.083, 0.167, 0.25, 0.333, 0.50, 0.75,
1, 1.5, 2, 3, 4, 5, 6, 7 and 8 h of injection. All blood samples were
centrifuged at 5000 × g for 15min at 4◦C. Plasma was separated
and stored at −20◦C until UV-HPLC analysis. Furthermore, the
total amount of urine and feces were collected in ice bags before
and after 12 and 24 h, followed by intermittent collection from
days 1 to 14 after each administration. The total volumes and
weights of each sample were measured and homogenized. An
appropriate quantity of each sample was stored at −20◦C until
UV-HPLC analysis.
Sample Treatment
Blood
An aliquot of 0.3mL plasma from each time-point was added
into a polypropylene centrifuge tube. Deproteinization was
performed with 0.3mLmethanol, followed by vigorous vortexing
for 3min. Samples were centrifuged at 10,000 × g for 10min
at 4◦C and supernatant fractions filtered through a 0.22µm
microbore cellulose membrane. A 200µL aliquot of each sample
was injected onto the HPLC system.
Urine
Urine sample (2mL) was poured into a 10mL polypropylene
plastic tube after filtration through a 0.22µmmicrobore cellulose
membrane. A stock solution of 2% metaphosphoric acid was
added to the tube until pH was maintained at 5–6, followed by
vigorous vortexing for 3min. The supernatant was loaded onto
Oasis HLB cartridge (3mL, 60 mg; Waters, Milford, MA, USA)
which was preconditioned with 6mL methanol and 6mL water
at a flow rate of 3mL min−1. Next, the cartridge was washed
with 6mL of 5% methanol/water (v/v). The filter was dried by
purging an airstream at a flow rate of 10mL min−1 for 4–5min,
and analytes finally eluted with 6mL methanol. Subsequently,
12mL TCMwas added, followed by vigorous vortexing for 3min
and centrifugation at 8000 × g for 10min. After removing the
aqueous layer, the solution was evaporated to dryness under a
nitrogen stream at 40◦C. Residues were reconstituted with 2mL
of 65%methanol and centrifuged at 10,000× g for 8min. Finally,
1mL supernatant was filtered through a 0.22µm microbore
cellulose membrane before injection into the UV- HPLC system.
Feces
Aliquots of homogenized feces (2 g) were placed in 30mL
polypropylene centrifuge tubes, and mixed with 8mL of 1%
metaphosphoric acid in MeOH/ACN/water (50:20:30, v/v/v).
The mixtures were vortexed vigorously for 3min, ultrasonicated
for 10min at room temperature, and centrifuged at 4000 × g
for 10min. The supernatant was collected and transferred into
a separate 30mL centrifuge tube. Yet again the same extraction
procedure was repeated. The two supernatants were combined
and dried under a nitrogen stream at 40◦C. To remove fat
from the sample, 6mL n-hexane was added into the remaining
solution, followed by vortexing for 3min and centrifugation at
8000 × g for 10min. To confiscate proteins from the sample,
2mL of 10% zinc acetate was added to the extract, vortexed for
3min, and centrifuged at 10,000 × g for 10min, followed by
separation of the resultant supernatant which was loaded onto
a HLB cartridge. The cleanup procedure described above was
similarly adopted forHLB. After elution, 6mL of water was added
to the eluted sample. Next, 12mL TCM was added, vortexed for
3min, and after centrifugation at 10,000 × g for 10min at 4◦C,
the sample was dried under a nitrogen stream at 40◦C. Dried
residues were reconstituted with 2mL of 65%methanol, vortexed
for 1min and centrifuged at 12500 × g for 10min. The solution
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was filtered through 0.22µm nylon Millipore chromatographic
filters and a 200µL aliquot subjected toHPLC for detection of the
parent drug and its main metabolites. Total recovery of the drug
in urine and feces was calculated with the following formula:
X =
Dc× V
Td ×Wt
× 100
X = % drug recovered
Dc= Drug concentration in urine or feces
V = Total volume of urine or feces
Td = Total dose given to the animal
Wt =Weight of animal
HPLC Conditions
All samples (plasma, urine, and feces) were analyzed using
HPLC (Waters 2695 series) combined with an ultraviolet detector
system with the wavelength set at 320 nm. Separation of
chromatographs was achieved using a ZORBAX SB-C 18 column
(250mm × 4.6mm i.d., 5µm, Agilent, USA) at a flow rate of
1mL min−1 at 30◦C. The gradient elution mode was set for
separation of Cyx and its mainmetabolites, with themobile phase
A containing 0.5% formic acid and mobile phase B containing
pure ACN. The gradient profile was set as follows: 0min, 88% A;
5min, 80% A; 26min, 72% A; 26.01min, 88% A; 30min, 88% A.
The injection volume was 40µL.
Method Validation
Limit of detection (LOD) and limit of quantification (LOQ) were
calculated based on signal-to-noise ratio of sample presented
with 3:1 and 10:1, respectively. To obtain standard curves and
linear range, 100µL of mixed standard solution of Cyx and
its metabolites was spiked in samples extracted and purified
using the above procedures. The concentrations of Cyx and its
metabolites ranged from 0.1 to 6.4µg mL−1 in urine and feces
while in plasma, the concentrations ranged from 0.02 to 10.24µg
mL−1. Calibration curves were generated using weighted least
squares linear regression (1/y) and calculated as y = ax ± b,
where y represents the area of analyte and x the concentration
of the drug. Correlation coefficient, intercept and slope of each
standard curve were calculated. Accuracy and precision were
determined by adding three different concentrations (1, 2, and
4 times the LOQ) to blank samples. For the intraday experiment,
five sets of each concentration were run while five replicates of
three concentrations were examined on five different days for
the inter-day experiment. Accuracy was calculated on the basis
of absolute recovery by comparing the extracted sample peak
area with standard solution peak area. Precision was estimated
as relative standard deviation (RSD).
Data Analysis
The non-compartmental model was applied to calculate
the pharmacokinetic parameters of Cyx and its metabolites
using the WinNonlin software program (5.2Version, Pharsight
Corporation, CA, USA) according to an earlier report (Cutler,
1978; Yamaoka et al., 1978). Maximum concentration in plasma
(Cmax) and time to reach at this concentration (Tmax) were
calculated from the concentration-time profile. The area under
first moment (AUMC0−∞) and area under concentration-
time curve (AUC0−∞) were calculated from zero to the last
determined concentration at infinity (Perrier and Mayersohn,
1982). The bioavailability (F) of Cyx after administration via
the PO and IM routes was calculated using the formula: F =
(DoseIV× AUCP.O)/(DosePO × AUCIV) × 100 and (DoseIV×
AUCIM)/(DoseIM × AUCIV) × 100, respectively. All descriptive
statistical parameters were presented as means and standard
deviation using Microsoft Excel 2010.
RESULTS
HPLC Method Validation
Linearity of the standard mixtures with different concentrations
in plasma (0.02–10.24µg mL−1) and urine or feces (0.1–6.4µg
mL−1) showed excellent results within the same day as well as
on different days. The correlation coefficient values of all five
metabolites indicating functional linear relationship at different
concentrations were>0.999 across the concentration ranges used
for all samples. The standard calibration curves obtained were
used to quantify the drug metabolites in plasma, urine and feces
of dogs and also to ensure accuracy of method. Furthermore,
based on evaluation of background noise with several matrices,
no interference peak was detected at the time of retention of the
test compound.
The LOD was 0.02µg mL−1 for Cyx, Cy1, Cy2, and Cy6, and
0.04µg mL−1 for Cy4 in dog plasma. In urine and feces, LOD of
all analytes was 0.1µg mL−1, based on a signal-to-noise ratio of
3:1. LOQ in dog plasma was 0.05µg mL−1 for all analytes, except
Cy4, for which an LOQ of 0.08µgmL−1 was obtained. LOQ of all
the analytes was 0.2µg mL−1 in feces and urine with acceptable
accuracy and precision at a signal-to-noise ratio of 10:1 (Table 1).
The accuracy and precision of this method were calculated at
specified concentration range within and at five different days.
The mean recovery rate was >80% in plasma and >70% in feces
and urine. Inter- and intra-day RSD were <10%, signifying that
the proposed method is accurate and precise for detection of Cyx
and its major metabolites (Cy1, Cy2, Cy4, and Cy6) in plasma,
urine, and feces.
Pharmacokinetics of Cyx and Its Main
Metabolites
Plasma pharmacokinetics of Cyx and its main metabolites
(Cy1, Cy2, Cy4, and Cy6) was evaluated after PO, IM, or IV
administration. The plasma concentration vs. time curves with
PO, IM, and IV routes are shown in Figures 1–3, respectively.
The Cyx concentration in plasma during PO administration
reached the maximum level (0.102 ± 0.009µg mL−1) at 5.83 ±
0.75 h after dosing and was below LOQ at 16 h. The maximum
concentrations of Cy1, Cy2, Cy4, and Cy6 were higher than
parent compound at 7 ± 0.63, 9.33 ± 1, 7.67 ± 0.52, and
7.67 ± 0.52 h, respectively, after dosing. Furthermore, plasma
concentrations of Cy1, Cy2, Cy4, and Cy6 reached below LOQ at
24 h after dosing, suggesting that these metabolites are retained in
the blood for a longer period than the parent compound, as the
terminal half-life (T1/2) of Cyx (6.15 ± 0.94 h) was significantly
lower than those of Cy1, Cy2, Cy4, and Cy6. Areas under the
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TABLE 1 | Method validation data of cyadox and its main metabolites in dog plasma, urine, and feces.
Sample Drugs Units Linearity concentration range Calibration equation Correlation coefficient (r) LOD LOQ
Plasma Cy0 µg mL−1 0.02–10.24 y = 82570x − 3830.5 0.999 0.02 0.05
Cy1 y = 122088x + 6241.9 0.9986 0.02 0.05
Cy2 y = 105565x + 4687.9 0.9996 0.02 0.05
Cy4 y = 120618x + 6246.9 0.9997 0.04 0.08
Cy6 y = 55387x − 132.05 0.9999 0.02 0.05
Feces Cy0 µg g−1 0.1–6.4 y = 114609x + 13972 0.9991 0.1 0.2
Cy1 y = 129119x + 7416.8 0.9993 0.1 0.2
Cy2 y = 111348x + 1263.5 0.9993 0.1 0.2
Cy4 y = 117914x − 4828.4 0.9992 0.1 0.2
Cy6 y = 61228x + 6817.7 0.999 0.1 0.2
Urine Cy0 µg mL−1 0.1–6.4 y = 115770x + 11250 0.9991 0.1 0.2
Cy1 y = 136069x + 5606.2 0.9997 0.1 0.2
Cy2 y = 104538x + 6599 0.9996 0.1 0.2
Cy4 y = 117520x + 5271.3 0.9994 0.1 0.2
Cy6 y = 90745x + 2336.2 0.9998 0.1 0.2
FIGURE 1 | Mean plasma concentration-time curves of cyadox and its
metabolites in dogs after single oral administration through gavage at
dose rate 40mg kg−1 b.w. in dogs. n = 6.
curve (AUC) of all the metabolites were considerably larger than
that of Cyx and oral bioavailability (F) of Cyx was only 4.75 ±
1.39% after PO administration, suggesting lower bioavailability.
The volume of distribution (Vz) and body clearance rate (CL) of
Cy1, Cy2, Cy4, and Cy6 were lower than that of Cyx (Table 2).
The concentration of Cyx following IM delivery at 2.33 ±
0.52 h was higher than that of its metabolites. AUC and T1/2 of
Cy1 were lower than the corresponding measurements of Cyx
and other main metabolites while Vz (2.3 ± 0.4 L kg−1) and
CL (1.59 ± 0.154 L h−1 kg−1) of Cyx were considerably lower,
relative to those of its metabolites. Mean resident times (MRT)
of Cy1, Cy2, Cy4, and Cy6 were greater than those of the parent
metabolite (Table 3). The concentration vs. time curves after IM
injection suggested that Cyx reaches the peak level earlier but is
quickly eliminated from plasma, compared to metabolites, which
showed a swift decrease in concentration but were detectable for
FIGURE 2 | Mean plasma concentration-time curves of cyadox and its
main metabolites after single intramuscular injection in dogs at the
dose rate of 10mg kg−1 b.w. n = 6.
up to 12 h after dosing, except Cy1, which was observed for up to
8 h (Figure 2).
The concentrations of Cyx and Cy2 during IV injection
were highest at the first time-point (0.033 h) whereas Cy1,
Cy4, and Cy6 showed a swift increase followed by decrease in
concentration. The T1/2 of Cyx (0.344 ± 0.08 h) was markedly
lower while AUC of Cyx (6.66 ± 1.21 h × µg mL−1) was
significantly higher, compared to all the metabolites. Vz and CL
of Cyx markedly lower than those of the metabolites, with Cy1
displaying the maximum Vz and CL values. Furthermore, the
steady-state volume of distribution (Vss) was the lowest for Cyx
(0.873± 0.07 L kg−1) and highest for Cy1 (100.23± 7.12 L kg−1).
MRT of Cyx was also lower than that of its metabolites (Table 4).
We observed a gradual increase in the concentrations of Cy1,
Cy4, and Cy6, in contrast to Cyx and Cy2 for which maximum
concentrations were observed at the first time-point (Figure 3).
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FIGURE 3 | Mean plasma concentration-time curves of cyadox and its
main metabolites after single intravenous injection in dogs at the dose
rate of 10mg kg−1 b.w. n = 6.
Mass Balance in Urine and Feces
Urine and feces concentrations vs. time curves of Cyx after
administration via the PO, IM, and IV routes are shown in
Figures 4, 5, respectively. The majority of Cyx was excreted
through feces upon PO delivery. The consistency and appearance
of feces and urine was normal during all collection periods. After
PO administration through gavage, the drug was detected for 7
days in feces and 4 days in urine. The maximum concentration in
feces (10.78 ± 0.38%) was observed on day 2, while in urine, the
concentration (4± 0.43%) was highest after 36 h. The cumulative
recovery percentage in feces and urine after PO dosing were
48.83± 1.99 and 15.3± 1.71%, respectively (Table 5).
The percentage recovery of Cyx in urine and feces after IM
injection was 43.67 ± 1.19 and 18.15 ± 0.83%, respectively. The
main route of excretion after IM injection was urine and the drug
was detected for up to 4 days in feces. In urine the drug was
detected for up to 3 days. The maximum concentration detected
at day 1.5 in feces (4.40 ± 0.37%) and after 1 day of injection
(13.49± 1.23%) in urine (Table 5).
Total drug recovery in feces and urine after IV injection was
17.11± 1.37 and 45.37± 1.46%, respectively. The concentration
of Cyx peaked after 72 h in feces, whereas in urine, the peak
level was observed after 12 h of IV injection. However, the drug
was recovered up to 4 days in feces and 3 days in urine after
IV injection. Elimination was highest in urine at the first time-
point and lowest in feces, compared to the PO and IM routes of
administration (Table 5).
DISCUSSION
While a number of studies on tissue depletion, determination
methods and toxicity of Cyx in food-producing animals have
been reported (Sestakova and Kopanica, 1988; Zhang et al., 2005;
Ding et al., 2006b; Huang et al., 2008, 2015), scarce information
is available on the pharmacokinetics and metabolism of Cyx
administered via different routes. In view of the relatively low
toxicity of Cyx and strong antibacterial effects, this study was
designed to evaluate the pharmacokinetics and metabolism of
Cyx and four of its major metabolites after administration via
PO, IM, and IV routes in beagle dogs. The PO dose was selected
on the basis of a previous study conducted in pigs (Zhao et al.,
2013), whereas IM and IV doses were established based on earlier
pharmacokinetic studies on mequindox, a well-known group
member of the Cyx family (Liu et al., 2011; Ding et al., 2012).
Cy1, Cy2, Cy4, and Cy6 were previously identified as major
metabolites of Cyx in food-producing animals (Zhao et al., 2013;
Huang et al., 2015), and therefore selected for investigation in
the current study. A highly selective and sensitive UV-HPLC
method allowing the simultaneous determination of Cyx and its
major metabolites in dog plasma, feces and urine was utilized for
comprehensive evaluation of metabolism and pharmacokinetic
profiles of Cyx in dogs.
The recovery rates of all five analytes in plasma of dog
were >80% using MeOH as the extraction solvent. After testing
various solvents alone or in combination for extraction of
analytes in urine and feces, best recovery (>70%) was achieved in
the presence of 1% metaphosphoric acid at a MeOH/ACN/water
ratio of 50:20:30 (v/v/v). Oasis HLB was superior to other
cartridges in terms of good recovery (>80% in plasma, >70% in
urine and feces) and lowmatrix interference. For the elution step,
ACN and MeOH were used. Ultimately, MeOH was established
as the best choice due to its good extraction efficiency.
In general, pharmacokinetic parameters differ according
to species, drug formulation, body condition, route of
administration, age, gender, and physiological status of
animals, all of which contribute to differences in drug efficacy
(Canga et al., 2009). In our study, the maximum concentration
(Cmax) of Cyx in plasma was 0.102 ± 0.009µg mL
−1 at
5.83 ± 0.75 h following PO administration, implying that Cyx
is quickly metabolized to its metabolites. Compared to the
parent metabolite Cy1, Cy2, Cy4, and Cy6 showed higher
concentrations and remained in plasma for longer time-periods
(Table 2). The highest concentration of Cyx observed following
delivery through IM or IV routes indicates that Cyx is partly
metabolized in the gastrointestinal tract (GIT) before absorption
due to the presence of certain microflora or enzymes to generate
metabolites. Our results were in accordance with data from
previous studies conducted in pigs (Zhao et al., 2013). Other
members of this group, i.e., quinocetone and mequindox
exhibit the same type of response in pigs and chickens when
administered IV, IM, or orally (Zhong et al., 2011; Ding et al.,
2012; Li et al., 2012). The lower AUC ratio of Cyx compared to
its metabolites upon administration through PO route, relative
to IM or IV injection, also supports the theory that this drug is
quickly metabolized in the GIT and converted to its metabolites.
Other recent in vitro and in vivo studies have validated that GIT
is the main metabolic pathway of this drug (Liu et al., 2009; Xu
et al., 2011). The terminal half-lives of Cyx when administered
orally through gavage and after IM and IV injections revealed
that Cyx is more rapidly eliminated from dog plasma than its
major metabolites. In an earlier study, the terminal half-lives of
Cyx in pig after PO and IV administration were 4.77 h (40mg
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TABLE 2 | Mean plasma pharmacokinetics of cyadox and its metabolites in dogs following oral administration through gavage at dose 40mg kg−1 b.w.
Parameters Units Cyx Cy1 Cy2 Cy4 Cy6
Lz h−1 0.115±0.02 0.089± 0.02 0.094±0.03 0.101± 0.02 0.085±0.01
T1/2 h 6.15±0.94 8.06± 1.76 7.97±2.63 7.06± 1.34 8.31±1.32
Tmax h 5.83±0.75 7± 0.63 9.33±1 7.67± 0.52 7.67±0.52
Cmax µg mL
−1 0.102±0.009 0.476± 0.04 0.188±0.03 0.336± 0.02 0.249±0.02
AUC0−∞ h × µg mL
−1 1.22±0.12 3.89± 0.38 3.06±0.28 3.61± 0.57 3.85±0.3
AUMC0−∞ h × h × µg mL
−1 13.8±3.29 47.04± 8.73 47.96±15.57 48.43± 15.42 60.23±10.58
VZ L kg−1 291.35±34.9 119.9± 24.3 148.25±38 112.74± 7.29 124.1±13.18
CL L h−1 kg−1 33.07±3.1 10.37± 1.08 13.16±1.26 11.31± 1.74 0.085±0.01
MRTlast h 7.32±0.43 8.93± 0.38 11.68±2.12 10.06± 0.5 10.61±0.39
F % 4.75±1.39
Lz, elimination rate constant; T1/2, elimination half-life; Tmax , time to reach maximum concentration; Cmax , maximum concentration of drug; AUC0−∞, area under plasma concentration-
time curve; AUMC0−∞, area under first moment curve; VZ, volume of distribution; CL, clearance rate; MRTlast, mean resident time; F, bioavailability of drug. Data are mean ± SD,
n = 6.
TABLE 3 | Mean plasma pharmacokinetic parameters of cyadox and its metabolites in dogs following intramuscular injection at dose 10mg kg−1 b.w.
Parameters Units Cyx Cy1 Cy2 Cy4 Cy6
Lz 1/h 0.702±0.06 0.953± 0.15 0.606± 0.07 0.621±0.08 0.566±0.09
T1/2 h 0.995±0.09 0.741± 0.1 1.16± 0.15 1.13±0.15 1.25±0.18
Tmax h 2.33±0.52 4.33± 0.52 5.66± 0.51 6.17±0.41 5.17±0.4
Cmax µg mL
−1 1.48±0.11 0.577± 0.1 0.863± 0.12 0.853±0.05 1.11±0.2
AUC0−∞ h × µg mL
−1 6.3±0.6 2.08± 0.4 4.57± 0.85 4.42±0.5 5.45±0.99
AUMC0−∞ h × h × µg mL
−1 23.02±3.27 9.02± 2.13 26.21± 6.05 27.55±3.61 30.32±5.94
Vz L kg−1 2.3±0.4 5.37± 1.46 3.83± 1.2 3.76±0.82 3.45±1.06
CL L h−1 kg−1 1.59±0.154 4.95± 0.9 2.26± 0.44 2.29±0.28 1.89±0.37
MRTlast h 3.58±0.19 4.22± 0.25 5.59± 0.32 6.12±0.28 5.45±0.24
F % 97.28±20.37
Lz, elimination rate constant; T1/2, elimination half-life; Tmax , time to reach maximum concentration; Cmax , maximum concentration of drug; AUC0−∞, area under plasma concentration-
time curve; AUMC0−∞, area under first moment curve; VZ, volume of distribution; CL, clearance rate; MRTlast, mean resident time; F, bioavailability of drug. Data are mean ± SD,
n = 6.
TABLE 4 | Mean plasma pharmacokinetic parameters of cyadox and its metabolites in dogs following intravenous injection at dose 10mg kg−1 b.w.
Parameter Units Cyx Cy1 Cy2 Cy4 Cy6
Lz 1/h 2.09±0.41 0.357± 0.03 0.909±0.09 0.944± 0.12 0.839±0.1
T1/2 h 0.344±0.08 1.95± 0.17 0.768±0.07 0.746± 0.11 0.836±0.09
Tmax h 0.033 0.958± 0.1 0.033 0.708± 0.1 1.42±0.2
Cmax µg mL
−1 9.89±0.3 0.089± 0.006 1.91±0.2 1.24± 0.17 1.08±0.25
AUC0−∞ h × µg mL
−1 6.66±1.21 0.313± 0.03 2.2±0.56 1.75± 0.34 2.33±0.66
AUMC 0−∞ h × h × µg mL
−1 3.92±1.21 0.983± 0.17 2.44±0.79 2.4± 0.5 4.73±1.28
Vz L kg−1 0.747±0.11 90.35± 6.9 5.29±1.24 6.52± 2.57 5.62±1.93
CL L h−1kg−1 1.55±0.32 32.25± 3.41 4.84±1.41 5.93± 1.34 4.64±1.51
MRTlast 0.556±0.07 1.78± 0.05 0.981±0.11 1.243± 0.05 1.91±0.15
Vss L kg−1 0.873±0.07 100.23± 7.12 5.15±1 8.11± 1.8 9.57±3.46
Lz, elimination rate constant; T1/2, elimination half-life; Tmax , time to reach maximum concentration; Cmax , maximum concentration of drug; AUC0−∞, area under plasma concentration-
time curve; AUMC0−∞, area under first moment curve; VZ, volume of distribution; CL, clearance rate; MRTlast, mean resident time; Vss, volume of distribution at steady state. Data are
mean ± SD, n = 6.
kg−1 b.w.) and 0.93 h (1mg kg−1 b.w.), respectively (Zhao et al.,
2013). The discrepancies in values obtained with both studies
may be attributable to species differences. Further Cmax of Cyx
after PO, IM, and IV injections revealed low amount of Cyx
in plasma after PO administration. Higher AUC and longer
elimination half-lives were detected for all major metabolites
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FIGURE 4 | Mean urine concentration-time curves of cyadox after oral,
intramuscular and intravenous routes of administration. n = 6.
FIGURE 5 | Mean feces concentration-time curves of cyadox after oral,
intramuscular and intravenous routes of administration. n = 6.
(Cy1, Cy2, Cy4, and Cy6), compared to Cyx, with all
administration routes in dog plasma, implying that the
majority of Cyx is transformed into its metabolites, which
possess good stability in plasma. Similar results were observed
during pharmacokinetic characterization of mequindox and
quinocetone, well-known members of this group (Ding et al.,
2012). Therefore, close attention should be paid to these
metabolites when identifying residue markers of Cyx in animal
tissues. The AUC andMRT values of all metabolites administered
via different routes at different doses indicate that Cyx is swiftly
absorbed and transformed into metabolites, which remain in
the blood for a long time. Furthermore, the concentration vs.
time curves obtained after all three routes of administration
revealed a rapid increase, followed by gradual decrease in the
concentration of Cyx and its metabolites, except in the case of
Cyx and Cy2 during IV route of administration, which showed
the highest concentrations at the first time-point (Figures 1–3).
This finding may be due to the reason that deoxygenation is
the initial and primary metabolic pathway of QdNOs, including
Cyx. Thus, Cy2 in blood samples was quickly present via the IV
route. The poor bioavailability (4.75 ± 1.39%) of Cyx and higher
Cmax values of its metabolites after PO administration indicate
that Cyx has an intestinal first-pass effect in dogs. In another
study the bioavailability of Cyx was determined as 2.75% in pig,
while among the other group members, the bio-availability of
mequindox in chicken, pigs and rats was evaluated as 17, 26,
and 37%, respectively (Liu et al., 2011; Ding et al., 2012; Li et al.,
2012). These findings suggest that the oral bioavailability of Cyx
is low, compared to its congeners. To endorse this hypothesis,
development of an intestinal and vascular access port (IVAP)
may be an effective approach for validating its livery or intestinal
first pass effect in animals. Additionally, the low concentrations
of Cyx in plasma observed after PO delivery suggests that this
route is suitable for intestinal infections while the IM route may
be the choice for systemic infections, as higher concentration of
Cyx was detected in the circulation than the minimum inhibitory
concentration of certain pathogenic bacterial species (Fan et al.,
2000; Huang et al., 2002).
Cyx is extensively metabolized in animal body involving
N-O group reduction, C = N cleavage, hydrogenation and
hydrolysis on the side chain. A number of in vitro and in vivo
experiments have revealed that Cyx can be metabolized through
both enzymatic and non-enzymatic pathways in both liver and
GIT (Zheng et al., 2011). Firstly, Cyx is quickly metabolized into
Cy1 and Cy2 through the process of deoxidation. Subsequently,
Cy1 and Cy2 are further deoxidized to form Cy4, which
converted into Cy6 through the process of hydrogenation (Xu
et al., 2011). In the current study, Cyx was excreted swiftly after
all three dosage routes. Fecal excretion was the major route
of elimination in dog following PO administration and renal
excretion established as the minor route. These results indicate
that most of the drug excreted in feces is not absorbed and thus
excreted in bile. Analogous findings have recently been reported
following PO administration of Cyx in rats, pigs, chickens, and
carp (Huang et al., 2015). In view of the finding that Cyx is
extensivelymetabolized bymicroflora of GIT (Xu et al., 2011), the
low amount of Cyx detected in dogs, compared to its metabolites,
may indicate similar extensive metabolization by microflora of
GIT in these animals. Cyx was detected up to 7 days in dog
feces and up to 4 days in urine after PO administration (Table 5).
The maximum concentration in feces was detected on day 2 and
in urine after 72 h of PO delivery, suggesting rapid elimination
from the body. More than 15 metabolites have been identified in
animal bodies in earlier studies (Huang et al., 2015). The total
percentage recovery of Cyx and its metabolites in feces and urine
was calculated as 48.83 ± 1.99% and 15.3 ± 1.71%, respectively,
suggesting that Cy1, Cy2, Cy4, and Cy6 are the main metabolites
in dog body comprising almost 64% of the drug excreted through
urine and feces. Progressive increase and a subsequent steady
decrease in drug concentrations in both urine and feces was also
observed (Figures 4, 5).
The fate of Cyx after IM and IV injection was determined
for the first time in this study. Total recovery rates via IM and
IV administration were 43.67 ± 1.19 and 45.37 ± 1.46% in
urine and 18.76 ± 0.9 and 17.11 ± 1.37% in feces, respectively,
suggesting that urine is the major route of excretion using
these two modes of delivery, with a lower amount detected in
feces (Table 5). This finding may be attributed to the fact that
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TABLE 5 | Percentage recovery of cyadox in feces and urine of dogs after oral, intramuscular, and intravenous administrations.
Days PO IM IV
Feces Urine Feces Urine Feces Urine
0.5 3.02±0.27 1.39± 0.27 2.17± 0.68 8.14± 1.17 0.96±0.08 18.8±1.31
1 6.04±0.75 2.92± 0.4 3.68± 0.46 13.49± 1.23 3.61±0.56 13±0.83
1.5 8.48±0.58 4± 0.43 4.40± 0.37 11.53± 1.19 4.88±0.74 7.45±0.87
2 10.78±0.38 3.73± 0.48 3.85± 0.38 6.70± 0.53 3.92±0.2 4.26±0.74
3 8.52±0.35 2.45± 0.46 2.70± 0.46 3.34± 0.79 2.76±0.26 1.86±0.49
4 6.27±0.78 0.81± 0.25 1.35± 0.41 ND 0.99±0.098 ND
5 4±0.6 ND ND ND ND ND
7 1.74±0.39 ND ND ND ND ND
Sum 48.83±1.99 15.3± 1.71 18.15± 0.83 43.67± 1.19 17.11±1.37 45.37±1.46
Total recovery 64.13±2.43 61.35± 1.59 62.48± 1.63
Data are mean ± SD, n = 6.
most of the drug does not enter the GIT when injected via the
IV or IM route, and is excreted from the body through renal
clearance. Earlier studies have reported that Cyx is extensively
metabolized by pig, chicken and rat liver microsomes (Liu et al.,
2009). The high recovery of Cyx and its main metabolites in
urine indicates that Cyx is comprehensively metabolized by dog
liver microsomes. The maximum percentage of drug following
administration through IV and IM routes was detected in urine
after 12 h and on day 1 and in feces on day 1.5, with a total
detection period of 4 days in feces and 3 days in urine. Moreover,
the concentration vs. time curves suggested a gradual increase
and subsequent swift decrease of Cyx in feces with all three routes
of administration, with high elimination times via PO, compared
to IM and IV delivery (Figure 4). In urine, the concentration
of Cyx was maximal after 12 h upon IV injection, following
which recovery decreased gradually, with detection up to 3 days.
Moreover, recovery was higher in the first collection period
after IM injection, compared to PO administration (Figure 5).
Our findings suggest that Cyx injected via IM and IV routes
is rapidly distributed, undergoes renal clearance evading the
first-pass effect of GIT, and is extensively metabolized by liver
microsomes. However, following IM injection, the concentration
was highest on day 1, indicating that Cyx enters the circulation
progressively, and the drug remained in the body for up to 3 days.
CONCLUSION
In worldwide, Cyx is being developed as a replacer of its
congeners because of low toxicity and strong antibacterial effects
in animals, compared to other QdNO drugs. It could be the
drug of choice in canine because they are more prone to
toxic effects against certain drugs which make a narrow range
of choices for them. The dog physiology is similar to other
mammals which could also help for risk assessment and safety
evaluation. This study provides a significant information on
pharmacokinetic and metabolism profiles of Cyx and its major
metabolites through different routes of administration which will
not only improve our understanding about pharmacology and
toxicology of Cyx, but also the safety evaluation and clinical use in
mammals.
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